SoftBank wants to push Neumann out of the CEO role ahead of the IPO.Technologyread more
The next three weeks are among the rockiest, on a historical basis, of the entire calendar.Trading Nationread more
An annual survey by Piper Jaffray finds iPhone that users willing to upgrade to newly released models declined from last year.Technologyread more
The UK's Civil Aviation Authority said Thomas Cook had now ceased trading and the regulator would work with the government to bring the more than 150,000 British customers...Europe Marketsread more
New York Fed President John Williams said Monday that the central bank acted quickly during last week's jolt to overnight lending markets and that the issue appears resolved...The Fedread more
The U.S. manufacturing sector recovered in September with activity growth hitting a five-month high, according to IHS Markit.Marketsread more
Harvard economist N. Gregory Mankiw said ultra-wealthy couples could split their fortunes in half through divorce and avoid paying a wealth tax proposed by presidential...Wealthread more
For incoming European Central Bank President Christine Lagarde, the U.S.-China trade war is the biggest threat to the global economy.Marketsread more
Samsung said on Monday it will launch the Galaxy Fold in the US on Sept. 27. The launch was delayed from April after reviewers found it broke easily. Samsung says it has fixed...Technologyread more
The holidays are a critical time for many brands, accounting for as much as 30% of a retailers annual sales. Heading into the gift-giving season, shoppers are expected to...Retailread more
Microsoft is looking for a new way to grab business from retailers as they fend off Amazon.Technologyread more
Sarepta Therapeutics CEO Doug Ingram told CNBC on Wednesday that accessing reimbursement from insurance companies for expensive, rare disease treatments is "always challenging."
But responding to a question about the $300,000-per-year cost for a Sarepta drug for Duchenne muscular dystrophy, Ingram defended the price tag.
"Sarepta is a small company. We have already invested $1 billion fighting Duchenne muscular dystrophy. And we're not done yet," he said on "Squawk Box."
Exondys 51 was approved for DMD on a conditional basis by the Food and Drug Administration last year, pending more testing to confirm results. It treats a mutation affecting about 13 percent of sufferers. The cost per-year is about $300,000 for a 55-pound patient. The price goes up for heavier recipients.
"This a societal question more than a Sarepta question," Ingram said. "I think it's the right decision for society to invest in finding solutions for these rare disorders."
Shares of Sarepta, which had a stock market value of $2.6 billion as of Tuesday's close on Wall Street, soared 9 percent Wednesday morning. It had risen 17 percent in premarket trading after the biopharma firm reported positive results from a clinical trial of another experimental DMD medicine. The treatment, golodirsen, targets a genetic mutation affecting about 8 percent of patients.
"Our goal is to treat 100 percent" of DMD suffers, said Ingram, who was appointed CEO of Sarepta in July. "The data that we have this morning shows we're on the right path."